CORAL GABLES, Fla., June 29, 2015 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Nasdaq:CPR X), a biopharmaceutical company focused on developing and commerciali zing innovative therapies for people with rare debilitating diseases, today a nnounced that the company has bee n added to the Russell 2000 ® , the Russell 3000 ® and Russell Global Indexes, following Russell’s annual reconsti tution on June 26, according to a preliminary list of additions posted June 12, 2015 on the FTSE Russell website.
Annual Russell indexes reconstitution captures the 4,000 larges t U.S. stocks as of the end of May, ranking them by total market capitalization. The Russell 2000 ® Index measures the performance of the small-cap segment of the U.S. equity market and is a subset of the Russell 3000 ® Index. Membership in the Russell 2000 ® , remains in place for one year. FTSE Russell determines membership for its Russell indexe s primarily by objective, market-capitalization rankings and style attributes.
“We are pleased that Catalyst Pharmaceuticals has been added as a member of the Russell 2000 ® ,” commented Patrick McEnany, president and chief executive officer. “This m embership validates our growth strategy and will enhance our visibility in the investment community.”
Russell indexes are widely used by investment managers and inst itutional investors for index funds and as benchmarks for active investment strategies. Approximately $5.7 trillion i n assets are benchmarked to the Russell’s U.S. indexes. Russell indexes are part of FTSE Russell, a leading global inde x provider.
About FTSE Russell
FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that me asure and benchmark mark ets and asset classes in more than 80 countries, covering 98% of the investable market g lobally and trading on over 25 exchanges worldwide.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases, including Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), inf antile spasms, and Tourette’s Di sorder. Catalyst’s lead candidate, Firdapse ® for the treatment of LEMS, recently compl eted testing in a global, mult i-center, pivotal Phase 3 trial resulting in positive top- line data. Firdapse ® for the treatment of LEMS has r eceived Breakthrough Therapy De signation from the U.S. Food and Drug Administration (FDA) and orphan drug designation for C MS. Firdapse ® is the first and only European approved drug for symptomatic treatment in adults with LEMS Catalyst is also developing CPP-115 to treat infantile spasms, epilepsy and other neurological conditions associated with reduced GABAergic signaling, like post -traumatic stress di sorder and Tourette’s Disorder. CPP-115 has been granted U.S. orphan drug designat ion for the treatment of infan tile spasms by the FDA and has been granted E.U. orphan medicinal product designa tion for the treatment of West Syndrome by the European Commission.
Help employers find you! Check out all the jobs and post your resume.